Clinical Trials List
2024-11-15 - 2027-02-16
Phase II
Recruiting4
ICD-10C00.0
Malignant neoplasm of external upper lip
ICD-10Z51.12
Encounter for antineoplastic immunotherapy
ICD-9140.0
Malignant neoplasm of upper lip, vermilion border
-
Trial Applicant
PAREXEL INTERNATIONAL CO., LTD.
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/04/01
Investigators and Locations
Co-Principal Investigator
- Mei-Chuan Chen Division of General Internal Medicine
- Chi-Li Chung Division of General Internal Medicine
- Jia-Ruey Tsai Division of General Internal Medicine
- Chun-Liang Chou
- Shang-Fu Hsu Division of General Internal Medicine
- Cheng-I Hsieh Division of General Internal Medicine
- Han-Pin Kuo 無
- Kai-Ling Lee Division of General Internal Medicine
- 倪承賦
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Ching-Shan Luo Division of General Internal Medicine
- JING-QUAN ZHENG Division of General Internal Medicine
- Po-Hao Feng Division of General Internal Medicine
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 葉金水 Division of Thoracic Medicine
- 黃國揚 Division of Thoracic Medicine
- 施穎銘 Division of Thoracic Medicine
- 詹博強 Division of Thoracic Medicine
- 陳正雄 Division of Thoracic Medicine
- 林俊維 Division of Thoracic Medicine
- 蔡偉宏 Division of Thoracic Medicine
- 林慶雄 Division of Thoracic Medicine
- 紀炳銓 Division of Thoracic Medicine
- 林明泰 Division of Thoracic Medicine
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- WEI-LI MA Division of Hematology & Oncology
- YEN-TING LIN Division of Hematology & Oncology
- Chia-Chi Lin Division of Hematology & Oncology
- 黃信端 Division of Hematology & Oncology
- 黃得瑞 Division of Hematology & Oncology
- JIN-YUAN SHIH Division of Hematology & Oncology
- 廖斌志 Division of Hematology & Oncology
- 吳尚俊 Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
15 participants
-
Global
180 participants
